HUP0301847A2 - Adatanszerin alkalmazása neurodegeneratív állapotok megelżzésére és kezelésére alkalmas gyógyszerkészítmények elżállítására - Google Patents

Adatanszerin alkalmazása neurodegeneratív állapotok megelżzésére és kezelésére alkalmas gyógyszerkészítmények elżállítására

Info

Publication number
HUP0301847A2
HUP0301847A2 HU0301847A HUP0301847A HUP0301847A2 HU P0301847 A2 HUP0301847 A2 HU P0301847A2 HU 0301847 A HU0301847 A HU 0301847A HU P0301847 A HUP0301847 A HU P0301847A HU P0301847 A2 HUP0301847 A2 HU P0301847A2
Authority
HU
Hungary
Prior art keywords
treatment
adatanserin
prevention
pharmaceutical compositions
neurodegenerative conditions
Prior art date
Application number
HU0301847A
Other languages
English (en)
Inventor
Magid Abdel-Megid Abou-Gharbia
James Edward Barrett
Wayne Everett Childers
John Allen Moyer
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0301847A2 publication Critical patent/HUP0301847A2/hu
Publication of HUP0301847A3 publication Critical patent/HUP0301847A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

A találmány neurodegeneratív rendellenességek, mégpedig krónikusfájdalom és más, rendellenes glutamát felszabadulással kapcsolatosrendellenesség kezelésére alkalmas gyógyszerkészítmények előállításáravonatkozik, A kezelés során adatanszerin vagy gyógyászatilagelfogadható sója terápiásan hatásos mennyiségét adják be az ilyenkezelésre szoruló betegnek. A találmány kiterjed az adamantinalkalmazására a fenti neurodegeneratív rendellenességek kezelésérealkalmas gyógyszerkészítmény előállítására is. Ó
HU0301847A 1999-11-12 2000-11-10 Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions HUP0301847A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43921999A 1999-11-12 1999-11-12
PCT/US2000/030973 WO2001034136A2 (en) 1999-11-12 2000-11-10 Use of adatanserin for the treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
HUP0301847A2 true HUP0301847A2 (hu) 2003-09-29
HUP0301847A3 HUP0301847A3 (en) 2004-01-28

Family

ID=23743796

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301847A HUP0301847A3 (en) 1999-11-12 2000-11-10 Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions

Country Status (22)

Country Link
EP (2) EP1547597A3 (hu)
JP (1) JP2003513915A (hu)
KR (1) KR100757226B1 (hu)
CN (1) CN100469368C (hu)
AT (1) ATE291919T1 (hu)
AU (1) AU773733B2 (hu)
BR (1) BR0015523A (hu)
CA (1) CA2390797A1 (hu)
CZ (1) CZ298535B6 (hu)
DE (1) DE60019166T2 (hu)
EA (1) EA006099B1 (hu)
ES (1) ES2235998T3 (hu)
HK (1) HK1046505B (hu)
HU (1) HUP0301847A3 (hu)
IL (1) IL149264A0 (hu)
MX (1) MXPA02004654A (hu)
NO (1) NO322371B1 (hu)
NZ (1) NZ518814A (hu)
PL (1) PL355014A1 (hu)
PT (1) PT1242089E (hu)
WO (1) WO2001034136A2 (hu)
ZA (1) ZA200204682B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019166T2 (de) * 1999-11-12 2006-05-11 Wyeth Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
DE60019166T2 (de) * 1999-11-12 2006-05-11 Wyeth Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen

Also Published As

Publication number Publication date
CZ298535B6 (cs) 2007-10-31
CZ20021629A3 (cs) 2003-06-18
MXPA02004654A (es) 2004-09-10
HUP0301847A3 (en) 2004-01-28
CA2390797A1 (en) 2001-05-17
IL149264A0 (en) 2002-11-10
EA006099B1 (ru) 2005-08-25
HK1046505A1 (en) 2003-01-17
KR100757226B1 (ko) 2007-09-11
JP2003513915A (ja) 2003-04-15
ZA200204682B (en) 2003-09-11
NO322371B1 (no) 2006-09-25
CN100469368C (zh) 2009-03-18
ATE291919T1 (de) 2005-04-15
BR0015523A (pt) 2002-10-22
DE60019166D1 (de) 2005-05-04
PT1242089E (pt) 2005-08-31
EA200200559A1 (ru) 2002-12-26
EP1547597A2 (en) 2005-06-29
CN1390128A (zh) 2003-01-08
HK1046505B (zh) 2005-06-03
WO2001034136A2 (en) 2001-05-17
AU773733B2 (en) 2004-06-03
EP1242089A2 (en) 2002-09-25
AU1656701A (en) 2001-06-06
NO20022187L (no) 2002-05-07
ES2235998T3 (es) 2005-07-16
PL355014A1 (en) 2004-03-22
NO20022187D0 (no) 2002-05-07
KR20020073132A (ko) 2002-09-19
DE60019166T2 (de) 2006-05-11
NZ518814A (en) 2005-08-26
EP1242089B1 (en) 2005-03-30
WO2001034136A3 (en) 2002-03-21
EP1547597A3 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
HUP0300030A2 (en) Bupropion metabolites and methods of their synthesis and use and pharmaceutical compositions containing them and and their use
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
GB0129260D0 (en) Pharmaceutical compositions and their uses
HUP0100786A2 (hu) Helyettesített 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanonok, felhasználásuk egyes központi és perifériás idegrendszeri betegségek kezelésére és e vegyületeket tartalmazó gyógyszerkészítmények
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
EP1482959A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
SI1404304T1 (sl) Tableta, obsegajoča cetirizin in psevdoefedrin
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
HUP0301847A2 (hu) Adatanszerin alkalmazása neurodegeneratív állapotok megelżzésére és kezelésére alkalmas gyógyszerkészítmények elżállítására
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
HUP0402381A2 (hu) A monohidroxi-karbamazepin alkalmazása hangulati és a figyelemmel kapcsolatos rendellenességek és idegfájdalom kezelésére alkalmas gyógyszer előállítására
HUP0101326A2 (hu) Paroxetinkompozíciók és eljárás az előállításukra
HUP0304095A2 (hu) Új, nagyhatású gyógyszerkészítmények
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
MXPA05005326A (es) Tableta que comprende efletirizina y pseudoefedrina.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees